Swiss antibody shop Numab strikes an immuno-oncology discovery deal with Japan’s Ono
Almost exactly two years after Intarcia turned to the Swiss antibody shop Numab Therapeutics for a stable multispecific antibody that would fit into a once- or twice-yearly therapy for diabetes, the crew at Numab are back with another carefully crafted discovery deal — this time switching focus to immuno-oncology.
Japan’s Ono Pharmaceutical turned to Pfäffikon, Switzerland-based Numab — in the Schwyz canton — to come up with a new, tailored antibody that could make a good combo with Opdivo, the big checkpoint they are partnered with Bristol-Myers Squibb on.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
